A Psychometric Study of the Multidimensional Fatigue Inventory to Assess Fatigue in Patients with Schizophrenia Spectrum Disorders

Hedlund, Lena; Gyllensten, Amanda Lundvik; Hansson, Lars

doi:10.1007/s10597-014-9746-3

Cited by 27 publications

(26 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The EORTC QLQ‐C30 questionnaire has been thoroughly validated, and the shortened QLQ‐C15‐PAL produces directly compatible scores . The MFI‐20 has been validated with a wide range of conditions and previous studies have shown good internal consistency for all subscales in the MFI‐20 and with a stable multidimensional factorial structure . Furthermore, studies have demonstrated the MFI‐20 to be sensitive in differentiating between chronically ill and healthy populations as well as able to identify changes in the MFI after other interventions such as exercise, counseling, and pharmacological interventions …”

Section: Discussionmentioning

confidence: 99%

“…27,30 The MFI-20 has been validated with a wide range of conditions and previous studies have shown good internal consistency for all subscales in the MFI-20 and with a stable multidimensional factorial structure. 36,37 Furthermore, studies have demonstrated the MFI-20 to be sensitive in differentiating between chronically ill and healthy populations as well as able to identify changes in the MFI after other interventions such as exercise, counseling, and pharmacological interventions. 30,[38][39][40][41] Despite the previous validation of the questionnaires used herein, the 3 additional evaluating questions developed for the current trial were originally included to provide an additional source of comparison for results gathered from the MFI-20 and EORTC QLQ-C15-PAL.…”

Section: Discussionmentioning

confidence: 99%

“…Cancer October 15, 2015 paired data was used to evaluate the differences in mean scores. A significance level of .05 was used for the primary outcome and a significance level of .01 was used for the secondary outcomes to adjust for the familywise error rate.…”

Section: Effects Of Melatonin On Physical Fatigue/lund Ramussen Et Almentioning

confidence: 99%

See 2 more Smart Citations

Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double‐blind placebo‐controlled crossover trial

Rasmussen

Olsen

Johnsen

et al. 2015

Cancer

View full text Add to dashboard Cite

BACKGROUND:Patients with advanced cancer often experience fatigue and other symptoms that negatively impact their quality of life. The current trial investigated the effect of melatonin on fatigue and other symptoms in patients with advanced cancer. METHODS: Patients who were aged 18 years, had a histologically confirmed stage IV cancer (TNM Classification), and who reported feeling significantly tired were recruited from the palliative care unit at the study institution. The study was a double-blind, randomized, placebo-controlled crossover trial. Patients received 1 week of melatonin at a dose of 20 mg or a placebo orally each night, before crossing over and receiving the opposite treatment for 1 week. Between the 2 periods, a washout period of 2 days was implemented. Outcomes were measured using the Multidimensional Fatigue Inventory (MFI-20) and The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Physical fatigue from the MFI-20 was the primary outcome. The primary analysis was a complete complier analysis (ie, it included only those patients who had consumed at least 5 capsules per week and who had answered the MFI-20 on days 1, 7, 10, and 17). Sensitivity analysis using multiple imputations including all randomized patients and all patients completing the intervention were conducted. RESULTS: A total of 72 patients were randomized. Fifty patients completed the intervention and 44 patients were complete compliers. No significant differences between the placebo and melatonin periods were found for physical fatigue, secondary outcomes, or explorative outcomes. CONCLUSIONS: In the current study, oral melatonin at a dose of 20 mg was not found to improve fatigue or other symptoms in patients with advanced cancer. Cancer 2015;121:3727-36.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double‐blind placebo‐controlled crossover trial

Rasmussen

Olsen

Johnsen

et al. 2015

Cancer

View full text Add to dashboard Cite

show abstract

“…The analysis of convergent construct validity showed a correlation of .68 (time 1) and .77 (time 2). No item was systematically identi ed as being di cult to answer [30].…”

Section: Primary Outcome Measuresmentioning

confidence: 99%

“…A study exploring the psychometric properties of the MFI in 93 out-patients with schizophrenia spectrum disorders reported a mean score on the general fatigue subscale of 13.4 (standard deviation (SD): 3.9) [30]. An earlier study reported a mean score of 16 (SD 3.2) for this sub-scale in 166 patients with bromyalgia and chronic widespread pain [49].…”

Section: Determination Of Sample Size and Power Calculationmentioning

confidence: 99%

Assessment of the efficacy of a fatigue management therapy in schizophrenia: study protocol for a randomized, controlled multi-centered study (ENERGY)

Raffard¹,

Rainteau²,

Bayard

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background Fatigue is a well-known common clinical feature of numerous chronic diseases including various forms of cancer, neurological disorders such as multiple sclerosis, and psychiatric disorders. A significant proportion of people with schizophrenia (30-60%) reportedly experience fatigue, which impacts negatively on participation in various activities, including work, study, leisure and social pursuits. Causes of fatigue in schizophrenia are poorly understood and there are no established treatments. Several evidence-based interventions for fatigue syndrome including psychoeducation, cognitive behavioral therapy, and graded exercise therapy have been shown to be effective in other medical conditions and could be adapted to address fatigue in schizophrenia patients. As there are no psychosocial or pharmacological interventions with proved efficacy for fatigue in schizophrenia, there is an urgent need for the development of strategies to improve fatigue management in schizophrenia.The aim of this project is to evaluate in a single blind randomized clinical trial the efficacy of a cognitive-behavioral therapy (CBT) intervention compared to treatment as usual (TAU) on fatigue as the main outcome in schizophrenia patients. Clinical symptoms, physical functioning, major cognitive functions, quality of life and functioning, treatment dosage, daily motor activity, biological markers with inflammatory markers are also considered as secondary outcomes. Methods/design 200 patients meeting the inclusion criteria will be randomized to either of the study arms (intervention or TAU). The ENERGY intervention will be delivered according to a standardized treatment manual comprising six modules addressing fatigue and sleep over 14 individual therapy sessions. The treatment encompasses core CBT principles of psycho-education, behavioral activation, behavioral experiments, cognitive restructuring, problem-solving and relapse prevention. Sessions will follow the traditional CBT structure of agenda setting, review of homework tasks, and introduction of a new concept/technique with collaborative discussions on how to implement such strategies in the participant’s day-to-day environment. Our primary endpoint will be the severity of fatigue assessed at baseline and at the 9-month follow-up using the “Multidimensional Fatigue Inventory” (MFI).Discussion The trial will provide the first test of CBT intervention for fatigue for patients with schizophrenia. This study will also test to what extent the treatment can be implemented in everyday practice.Trial Registration : ClinicalTrials.gov Identifier: NCT04332601. Registered on April 10, 2020

show abstract

Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy

Binz

Osmanovic

Thomas

et al. 2022

Ann Clin Transl Neurol

View full text Add to dashboard Cite

Objective Fatigue is a common and burdensome symptom of spinal muscular atrophy. Given its complex interactions, different dimensions of fatigue need to be investigated. The Multidimensional Fatigue Inventory is a widely used instrument that captures five distinct dimensions. The aim of this study was to investigate the validity and reliability of the German Multidimensional Fatigue Inventory in spinal muscular atrophy and to evaluate the presence of clinically relevant fatigue. Methods One hundred and forty adult spinal muscular atrophy patients completed the Multidimensional Fatigue Inventory in a nationwide, multicenter, cross‐sectional study. Structural validity was explored using principal component analysis. Cronbach’s α was calculated to evaluate internal consistency. Convergent validity was assessed by correlation with a Visual Analog Scale for fatigue and the EuroQol‐Five Dimension‐Five Level Scale as a measure of quality of life. Results The original five‐component model of the questionnaire constituted an acceptable fit. Internal consistency and convergent validity of general, physical, mental fatigue, and reduced activity were good. We observed a floor effect for mental fatigue. While physical fatigue exceeded the cutoff for clinically relevant fatigue, all dimensions but reduced motivation correlated negatively with quality of life. Age, depression, and ≥4 copies of the survival motor neuron 2 gene were associated with higher general/physical fatigue; unemployed participants reported higher scores for reduced activity/motivation. Interpretation The Multidimensional Fatigue Inventory is a valid and reliable instrument to assess different dimensions of fatigue in spinal muscular atrophy. Fatigue is a relevant problem in spinal muscular atrophy and its assessment should be incorporated into standard care.

show abstract

A Psychometric Study of the Multidimensional Fatigue Inventory to Assess Fatigue in Patients with Schizophrenia Spectrum Disorders

Cited by 27 publications

References 21 publications

Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double‐blind placebo‐controlled crossover trial

Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double‐blind placebo‐controlled crossover trial

Assessment of the efficacy of a fatigue management therapy in schizophrenia: study protocol for a randomized, controlled multi-centered study (ENERGY)

Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy

Contact Info

Product

Resources

About